GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• GSK has a consensus “Hold” rating from 11 brokerages, with seven holds, two sells, one buy and one strong buy. The average 12-month price target is $56.50, compared with the stock’s recent price of $49.62.
• GSK reported quarterly EPS of $1.36, beating estimates of $1.27, while revenue rose 5.3% year over year to $11.14 billion. The company also increased its quarterly dividend to $0.4515, implying an annualized yield of about 3.6%.
• Institutional ownership stands at 15.74%, with several investors increasing their positions. GSK is also expanding its oncology pipeline through licensing and acquisition deals, including agreements with HUTCHMED and Chimagen Biosciences.

Shares of GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) have been given a consensus rating of "Hold" by the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, seven have given a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $56.50.

Several research analysts have recently weighed in on GSK shares. Berenberg Bank set a $60.00 price target on shares of GSK in a report on Tuesday, September 15th. Weiss Ratings lowered GSK from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, July 29th. Royal Bank Of Canada initiated coverage on GSK in a research report on Tuesday, September 8th. They set a "sector perform" rating for the company. Jefferies Financial Group upgraded GSK to a "strong-buy" rating in a research note on Friday, July 17th. Finally, Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a report on Saturday, August 1st.

Institutional Investors Weigh In On GSK

A number of institutional investors and hedge funds have recently bought and sold shares of GSK. QRG Capital Management Inc. grew its stake in GSK by 7.6% in the 2nd quarter. QRG Capital Management Inc. now owns 191,512 shares of the pharmaceutical company's stock worth $10,039,000 after buying an additional 13,519 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of GSK by 3.3% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 18,135 shares of the pharmaceutical company's stock valued at $951,000 after buying an additional 585 shares in the last quarter. Security National Bank of SO Dak purchased a new stake in shares of GSK during the 2nd quarter valued at $38,000. Keystone Financial Planning Inc. lifted its holdings in shares of GSK by 3,114.8% during the 2nd quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company's stock worth $10,253,000 after acquiring an additional 189,506 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of GSK by 1.8% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 36,293 shares of the pharmaceutical company's stock worth $1,902,000 after acquiring an additional 641 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Trading Down 0.2%

Shares of GSK opened at $49.62 on Friday. GSK has a twelve month low of $39.29 and a twelve month high of $61.69. The stock has a market cap of $100.37 billion, a PE ratio of 15.52, a P/E/G ratio of 2.12 and a beta of 0.35. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81. The business's 50-day moving average price is $50.90 and its 200-day moving average price is $52.29.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The company had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.02 billion. During the same quarter in the previous year, the company earned $0.47 earnings per share. GSK's revenue for the quarter was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities analysts forecast that GSK will post 4.81 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be given a $0.4515 dividend. This represents a $1.81 annualized dividend and a dividend yield of 3.6%. This is a positive change from GSK's previous quarterly dividend of $0.44. The ex-dividend date is Friday, August 14th. GSK's dividend payout ratio (DPR) is currently 55.63%.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK entered an exclusive global development and licensing agreement with HUTCHMED for HMPL-A830, an experimental cancer treatment aimed at colorectal, pancreatic and lung cancers. GSK will gain worldwide rights, while paying HUTCHMED $110 million upfront, up to $1.3 billion in potential milestones and tiered royalties. The deal expands GSK’s oncology pipeline, though the payments are dependent on development and commercial success. GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity
• Positive Sentiment: GSK agreed to acquire full global rights to a trispecific T-cell engager from Chimagen Biosciences in a transaction worth up to $750 million. The asset is still experimental, but the deal reinforces CEO Luke Miels’ focus on building a larger oncology business and diversifying future growth beyond existing products. GSK Adds Another Cancer Drug in a $750 Million Deal
• Positive Sentiment: Berenberg upgraded GSK to Buy from Hold and raised its price target to 2,200 pence from 2,000 pence, citing momentum from the company’s recent pipeline additions. The upgrade suggests some analysts believe the market is undervaluing GSK’s oncology investments and longer-term growth prospects. Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum
• Neutral Sentiment: Recent investor-conference presentations provided additional management commentary on GSK’s strategy, pipeline and growth priorities, but no specific new guidance or major financial update was identified in the available reports.
• Neutral Sentiment: A $3.3 million philanthropic commitment involving the North Carolina GSK Foundation supports workforce development in western North Carolina. The initiative is unlikely to have a material effect on GSK’s earnings or valuation.
• Negative Sentiment: Labor advocates called for preserving jobs at GSK’s Dresden vaccine plant in Germany, highlighting potential workforce and restructuring concerns. The financial impact is unclear, but any plant changes could create execution costs or reputational pressure.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.